Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alyson Garcia

Obstetrics & Gynecology Austin, TX Medical Doctor

NPI 1316207269 CMS profile 1390572

12200 Renfert Way, Austin, TX 78758

Open in the dashboard

General payments

$3,457

169 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alyson Garcia of Austin, TX is reported in the CMS Open Payments database as having received $3,457 across 169 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $455 18
2024 General $828 31
2023 General $414 19
2022 General $261 8
2021 General $348 30
2020 General $455 25
2019 General $697 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alyson Garcia
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Alyson Garcia were reported at $455. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Alyson Garcia Obstetrics & Gynecology median Middle half National median
2019 $697 $172 $62–$391 $163
2020 $455 $94 $36–$222 $114
2021 $348 $136 $42–$369 $132
2022 $261 $160 $50–$433 $149
2023 $414 $169 $56–$423 $160
2024 $828 $152 $50–$371 $164
2025 $455 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Exeltis, USA Inc. $877 75 payments
  2. Novo Nordisk Inc $458 21 payments
  3. AbbVie, Inc. $275 9 payments
  4. Medtronic, Inc. $192 3 payments
  5. TherapeuticsMD, Inc. $155 9 payments
  6. Biogen, Inc. $153 7 payments
  7. Covidien LP $134 1 payment
  8. Innovation Technologies Inc $132 1 payment
  9. Shield Therapeutics Inc $128 3 payments
  10. Evofem Biosciences, Inc. $118 7 payments
  11. Other $835 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,457 169 payments
Products named General payments · program years 2019–2025
  1. SLYND $465 37 payments
  2. Vitafol Ultra $333 33 payments
  3. Wegovy $265 14 payments
  4. Orilissa $147 3 payments
  5. Ozempic $145 3 payments
  6. SurgiSleeve $134 1 payment
  7. Irrisept $132 1 payment
  8. ACCRUFER $128 3 payments
  9. Zurzuvae $119 6 payments
  10. Axonics $116 2 payments
  11. Other $1,587 74 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

169 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record